New Agents for Treatment of Lymphomas: Which Ones Will Succeed?
F B Hagemeister, MD, The Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. March 2008

Elderly Patients with Bulky NHL Who Achieve a PR to Chemotherapy May Benefit from Local Radiotherapy (11/17/2009)
Researchers from Germany have reported that elderly patients with aggressive non-Hodgkin’s lymphoma (NHL) with bulky disease who achieve a partial response (PR) after chemotherapy may benefit from local radiotherapy. The details of this study were presented at the 2009 meeting of the American Society of Therapeutic Radiology and Oncology (ASTRO) in the first week of November.

Gemzar® Effective for Peripheral T-cell Lymphomas and Mycosis Fungoides (11/9/2009)
Researchers from Italy have reported that Gemzar® (gemcitabine) is effective single-agent therapy for previously treated patients with peripheral T-cell lymphoma (PTCL) and mycosis fungoides (MF). The details of this study appeared in an early online publication in the Annals of Oncology on November 3, 2009.

Rituxan®-Fludara® Highly Effective for Extranodal MALT B-cell Lymphomas (11/9/2009)
Researchers from Spain have reported that Rituxan® (rituximab) and Fludara® (fludarabine) produces complete remissions in 90% of newly diagnosed patients with extranodal marginal-zone lymphomas of the mucosal-associated lymphoid tissue (MALT) type. The details of this study were published in the November 15, 2009 issue of Cancer.

Xcytrin® (Motexafin Gadolinium) May Improve Results of Zevalin® for Treatment of Refractory NHL (10/26/2009)
Researchers from the Robert H Lurie Comprehensive Cancer Center have reported that the addition of Xcytrin® to Zevalin® ([90Y] ibritumomab tiuxetan) may improve treatment of patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL). The details of this study appeared early online in Clinical Cancer Research.

Torisel® Active in Relapsed or Refractory Mantle Cell Lymphoma (10/21/2009)
Researchers from Germany have reported that Torisel® (temsirolimus) improves progression-free survival (PFS) in patients with relapsed or refractory mantle cell lymphoma (MCL). The details of this Phase III study were published in the August, 2009 issue of the Journal of Clinical Oncology.